MENU
+Compare
ATXS
Stock ticker: NASDAQ
AS OF
Nov 26, 04:59 PM (EDT)
Price
$12.62
Change
+$0.28 (+2.27%)
Capitalization
719.27M

ATXS Astria Therapeutics Forecast, Technical & Fundamental Analysis

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases... Show more

Industry: #Biotechnology
ATXS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for ATXS with price predictions
Nov 25, 2025

Aroon Indicator for ATXS shows an upward move is likely

ATXS's Aroon Indicator triggered a bullish signal on November 10, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 189 similar instances where the Aroon Indicator showed a similar pattern. In of the 189 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ATXS advanced for three days, in of 263 cases, the price rose further within the following month. The odds of a continued upward trend are .

ATXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for ATXS moved out of overbought territory on November 11, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 53 cases where ATXS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on November 24, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ATXS as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ATXS turned negative on November 03, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATXS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ATXS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.214) is normal, around the industry mean (27.690). P/E Ratio (0.000) is within average values for comparable stocks, (51.985). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.895). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (322.277).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
ATXS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

ATXS is expected to report earnings to -55 cents per share on March 05

Astria Therapeutics ATXS Stock Earnings Reports
Q4'25
Est.
$-0.55
Q3'25
Missed
by $0.13
Q2'25
Missed
by $0.08
Q1'25
Missed
by $0.13
Q4'24
Beat
by $0.01
The last earnings report on November 12 showed earnings per share of -55 cents, missing the estimate of -41 cents. With 1.22M shares outstanding, the current market capitalization sits at 719.27M.
A.I. Advisor
published General Information

General Information

a developer of new medicines for the treatment of cardiovascular, metabolic and inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
75 State Street
Phone
+1 617 349-1971
Employees
59
Web
https://www.astriatx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AZMAX20.150.08
+0.40%
Virtus NFJ Emerging Markets Value A
EXTGX60.11N/A
N/A
Eaton Vance Tx-Mgd Growth 1.2 A
ADGAX26.55N/A
N/A
AB Core Opportunities A
VSTIX66.54N/A
N/A
VALIC Company I Stock Index
SSKEX82.72N/A
N/A
State Street Emerging Markets Eq Idx K

ATXS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with XENE. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
-0.08%
XENE - ATXS
49%
Loosely correlated
+4.49%
SYRE - ATXS
49%
Loosely correlated
+8.27%
RGNX - ATXS
48%
Loosely correlated
+9.98%
ORKA - ATXS
46%
Loosely correlated
+2.18%
CRNX - ATXS
45%
Loosely correlated
+1.98%
More